Kennon Heard
Concepts (635)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Acetaminophen | 39 | 2023 | 243 | 9.090 |
Why?
| Chemical and Drug Induced Liver Injury | 15 | 2023 | 134 | 5.150 |
Why?
| Analgesics, Non-Narcotic | 20 | 2022 | 119 | 4.730 |
Why?
| Drug Overdose | 30 | 2022 | 293 | 4.410 |
Why?
| Emergency Service, Hospital | 40 | 2023 | 1835 | 3.830 |
Why?
| Poisoning | 17 | 2017 | 111 | 3.280 |
Why?
| Poison Control Centers | 11 | 2023 | 83 | 2.880 |
Why?
| Alanine Transaminase | 14 | 2023 | 146 | 2.820 |
Why?
| Acetylcysteine | 11 | 2023 | 149 | 2.780 |
Why?
| Cannabis | 9 | 2020 | 381 | 2.660 |
Why?
| Cocaine | 10 | 2011 | 152 | 2.630 |
Why?
| Prescription Drugs | 9 | 2018 | 112 | 2.400 |
Why?
| Analgesics, Opioid | 8 | 2023 | 792 | 1.760 |
Why?
| Antidotes | 9 | 2020 | 127 | 1.650 |
Why?
| Legislation, Drug | 5 | 2017 | 73 | 1.610 |
Why?
| Cysteine | 4 | 2017 | 175 | 1.500 |
Why?
| Antipsychotic Agents | 7 | 2019 | 184 | 1.450 |
Why?
| Marijuana Use | 4 | 2021 | 160 | 1.380 |
Why?
| Male | 101 | 2022 | 56664 | 1.320 |
Why?
| Medication Errors | 5 | 2015 | 88 | 1.270 |
Why?
| Humans | 152 | 2023 | 117052 | 1.230 |
Why?
| Cocaine-Related Disorders | 5 | 2011 | 105 | 1.190 |
Why?
| Pain | 9 | 2020 | 719 | 1.180 |
Why?
| Toxicology | 4 | 2021 | 36 | 1.160 |
Why?
| Female | 95 | 2022 | 60635 | 1.160 |
Why?
| Adult | 73 | 2022 | 31003 | 1.150 |
Why?
| Emergency Medicine | 6 | 2019 | 236 | 1.150 |
Why?
| Drug Packaging | 2 | 2017 | 43 | 1.150 |
Why?
| Medication Reconciliation | 2 | 2016 | 25 | 1.050 |
Why?
| Dose-Response Relationship, Drug | 16 | 2017 | 1889 | 1.030 |
Why?
| Antidepressive Agents, Tricyclic | 5 | 2014 | 29 | 0.970 |
Why?
| Spider Bites | 5 | 2019 | 10 | 0.960 |
Why?
| Diphenhydramine | 4 | 2023 | 30 | 0.950 |
Why?
| Akathisia, Drug-Induced | 2 | 2020 | 6 | 0.940 |
Why?
| Middle Aged | 54 | 2022 | 27173 | 0.930 |
Why?
| Antivenins | 5 | 2019 | 55 | 0.930 |
Why?
| Young Adult | 30 | 2020 | 10675 | 0.920 |
Why?
| Thiazoles | 4 | 2009 | 113 | 0.920 |
Why?
| Prescription Drug Monitoring Programs | 1 | 2023 | 13 | 0.900 |
Why?
| Spider Venoms | 4 | 2019 | 12 | 0.890 |
Why?
| Heart Arrest | 8 | 2018 | 289 | 0.880 |
Why?
| Benzodiazepines | 5 | 2011 | 116 | 0.860 |
Why?
| Referral and Consultation | 2 | 2020 | 640 | 0.860 |
Why?
| Muscarinic Antagonists | 3 | 2023 | 26 | 0.860 |
Why?
| Decision Support Systems, Clinical | 2 | 2023 | 180 | 0.850 |
Why?
| Seizures | 6 | 2011 | 347 | 0.840 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 299 | 0.810 |
Why?
| Physostigmine | 2 | 2020 | 10 | 0.800 |
Why?
| Piperazines | 4 | 2009 | 314 | 0.800 |
Why?
| Lorazepam | 2 | 2020 | 23 | 0.800 |
Why?
| Emergency Treatment | 4 | 2015 | 111 | 0.800 |
Why?
| Delirium | 2 | 2020 | 67 | 0.790 |
Why?
| Black Widow Spider | 4 | 2019 | 9 | 0.790 |
Why?
| Medical History Taking | 3 | 2018 | 114 | 0.780 |
Why?
| Dopamine Uptake Inhibitors | 3 | 2011 | 52 | 0.780 |
Why?
| Suicide, Attempted | 5 | 2012 | 316 | 0.750 |
Why?
| Abdominal Pain | 2 | 2019 | 132 | 0.740 |
Why?
| Anti-Arrhythmia Agents | 4 | 2014 | 105 | 0.740 |
Why?
| Retrospective Studies | 30 | 2022 | 12825 | 0.730 |
Why?
| Back Pain | 1 | 2020 | 44 | 0.720 |
Why?
| Hospitals, Pediatric | 4 | 2018 | 489 | 0.720 |
Why?
| Vasoconstrictor Agents | 4 | 2009 | 120 | 0.710 |
Why?
| Patient Handoff | 1 | 2020 | 27 | 0.700 |
Why?
| Buprenorphine | 2 | 2020 | 141 | 0.700 |
Why?
| Free Radical Scavengers | 2 | 2011 | 89 | 0.690 |
Why?
| Ketorolac | 1 | 2019 | 17 | 0.670 |
Why?
| Haloperidol | 1 | 2019 | 35 | 0.670 |
Why?
| Social Work | 1 | 2020 | 72 | 0.660 |
Why?
| Pharmacoepidemiology | 1 | 2018 | 21 | 0.650 |
Why?
| Prospective Studies | 18 | 2023 | 6389 | 0.650 |
Why?
| Colorado | 15 | 2021 | 4121 | 0.650 |
Why?
| Substance-Related Disorders | 5 | 2012 | 947 | 0.640 |
Why?
| Tertiary Care Centers | 3 | 2017 | 125 | 0.640 |
Why?
| Gastric Lavage | 3 | 2009 | 9 | 0.630 |
Why?
| Vomiting | 6 | 2019 | 123 | 0.630 |
Why?
| Child | 28 | 2023 | 18877 | 0.630 |
Why?
| Immunoglobulin Fab Fragments | 4 | 2019 | 69 | 0.620 |
Why?
| Cannabinoids | 3 | 2017 | 116 | 0.600 |
Why?
| Hypotension | 2 | 2022 | 115 | 0.600 |
Why?
| Drug Storage | 2 | 2017 | 58 | 0.600 |
Why?
| Accidents, Home | 1 | 2017 | 29 | 0.590 |
Why?
| Medical Marijuana | 2 | 2019 | 97 | 0.590 |
Why?
| Pulmonary Embolism | 3 | 2021 | 180 | 0.580 |
Why?
| Plant Preparations | 2 | 2015 | 23 | 0.580 |
Why?
| Fibrin Fibrinogen Degradation Products | 2 | 2007 | 80 | 0.570 |
Why?
| Calcium Gluconate | 1 | 2016 | 4 | 0.570 |
Why?
| Quaternary Ammonium Compounds | 1 | 2016 | 45 | 0.560 |
Why?
| Hypocalcemia | 1 | 2016 | 30 | 0.550 |
Why?
| Mobile Applications | 1 | 2018 | 144 | 0.550 |
Why?
| Health Records, Personal | 1 | 2016 | 24 | 0.550 |
Why?
| Practice Patterns, Physicians' | 3 | 2023 | 1191 | 0.540 |
Why?
| Nonprescription Drugs | 4 | 2016 | 67 | 0.530 |
Why?
| Antidepressive Agents | 2 | 2012 | 196 | 0.530 |
Why?
| Blood Proteins | 1 | 2017 | 235 | 0.530 |
Why?
| Treatment Outcome | 18 | 2020 | 9257 | 0.530 |
Why?
| Liver | 6 | 2022 | 1744 | 0.530 |
Why?
| Fat Emulsions, Intravenous | 2 | 2014 | 30 | 0.520 |
Why?
| Child, Preschool | 13 | 2018 | 9323 | 0.520 |
Why?
| Drug-Related Side Effects and Adverse Reactions | 5 | 2023 | 243 | 0.510 |
Why?
| Prescription Drug Misuse | 1 | 2015 | 38 | 0.510 |
Why?
| Emergency Medical Services | 4 | 2016 | 588 | 0.510 |
Why?
| Electrocardiography | 5 | 2013 | 548 | 0.510 |
Why?
| Infant | 12 | 2018 | 8122 | 0.500 |
Why?
| Adolescent | 27 | 2020 | 18214 | 0.480 |
Why?
| Asymptomatic Diseases | 2 | 2013 | 81 | 0.470 |
Why?
| Electronic Health Records | 3 | 2023 | 809 | 0.470 |
Why?
| Crime | 2 | 2011 | 61 | 0.470 |
Why?
| Observer Variation | 3 | 2010 | 307 | 0.470 |
Why?
| Arrhythmias, Cardiac | 3 | 2022 | 273 | 0.460 |
Why?
| Double-Blind Method | 7 | 2020 | 1670 | 0.460 |
Why?
| Adrenergic alpha-2 Receptor Agonists | 1 | 2013 | 25 | 0.460 |
Why?
| Energy Drinks | 1 | 2013 | 4 | 0.450 |
Why?
| Performance-Enhancing Substances | 1 | 2013 | 7 | 0.450 |
Why?
| Aged | 27 | 2019 | 19359 | 0.450 |
Why?
| Accidents | 1 | 2013 | 40 | 0.450 |
Why?
| Bradycardia | 1 | 2013 | 48 | 0.440 |
Why?
| Dronabinol | 4 | 2021 | 118 | 0.440 |
Why?
| Diet Surveys | 1 | 2013 | 84 | 0.440 |
Why?
| Poisons | 2 | 2023 | 21 | 0.440 |
Why?
| Plasmapheresis | 1 | 2013 | 21 | 0.440 |
Why?
| Hematemesis | 1 | 2012 | 3 | 0.440 |
Why?
| Amphotericin B | 1 | 2013 | 30 | 0.440 |
Why?
| Phytotherapy | 1 | 2013 | 68 | 0.440 |
Why?
| Stomach Diseases | 1 | 2012 | 17 | 0.430 |
Why?
| beta-Alanine | 1 | 2012 | 20 | 0.430 |
Why?
| Foreign Bodies | 2 | 2011 | 97 | 0.430 |
Why?
| Aspartate Aminotransferases | 3 | 2010 | 92 | 0.430 |
Why?
| Ethers | 1 | 2012 | 16 | 0.430 |
Why?
| Sulfonylurea Compounds | 2 | 2010 | 44 | 0.430 |
Why?
| Alcohol Drinking | 4 | 2012 | 649 | 0.430 |
Why?
| Antithrombins | 1 | 2012 | 50 | 0.420 |
Why?
| Disease Models, Animal | 9 | 2011 | 3648 | 0.420 |
Why?
| Citalopram | 1 | 2012 | 27 | 0.420 |
Why?
| Liver Function Tests | 7 | 2020 | 106 | 0.420 |
Why?
| Drug Administration Schedule | 5 | 2014 | 723 | 0.410 |
Why?
| Opioid-Related Disorders | 2 | 2020 | 426 | 0.410 |
Why?
| C-Peptide | 2 | 2010 | 139 | 0.410 |
Why?
| Antifungal Agents | 1 | 2013 | 134 | 0.410 |
Why?
| Propafenone | 1 | 2011 | 2 | 0.410 |
Why?
| Thiophenes | 1 | 2012 | 106 | 0.410 |
Why?
| Genetic Predisposition to Disease | 1 | 2020 | 2227 | 0.400 |
Why?
| Burns | 2 | 2015 | 246 | 0.400 |
Why?
| Firesetting Behavior | 1 | 2011 | 1 | 0.400 |
Why?
| Aged, 80 and over | 15 | 2018 | 6454 | 0.400 |
Why?
| Benzimidazoles | 1 | 2012 | 138 | 0.400 |
Why?
| Infusions, Intravenous | 6 | 2013 | 376 | 0.400 |
Why?
| Charcoal | 4 | 2006 | 23 | 0.400 |
Why?
| Clinical Enzyme Tests | 2 | 2013 | 11 | 0.390 |
Why?
| Temperance | 2 | 2010 | 14 | 0.390 |
Why?
| Administration, Intravenous | 4 | 2016 | 133 | 0.390 |
Why?
| Chemical and Drug Induced Liver Injury, Chronic | 1 | 2011 | 9 | 0.380 |
Why?
| Brain Edema | 1 | 2011 | 60 | 0.380 |
Why?
| Cholinergic Antagonists | 1 | 2011 | 27 | 0.380 |
Why?
| Self-Injurious Behavior | 1 | 2012 | 113 | 0.380 |
Why?
| Amitriptyline | 2 | 2001 | 21 | 0.380 |
Why?
| Evidence-Based Medicine | 4 | 2023 | 682 | 0.380 |
Why?
| Blood Chemical Analysis | 3 | 2021 | 94 | 0.370 |
Why?
| Immunologic Factors | 2 | 2019 | 222 | 0.370 |
Why?
| Liver Failure | 1 | 2011 | 84 | 0.370 |
Why?
| Tachycardia, Ventricular | 1 | 2012 | 149 | 0.370 |
Why?
| Population Surveillance | 1 | 2013 | 406 | 0.370 |
Why?
| Anaphylaxis | 2 | 2012 | 147 | 0.370 |
Why?
| Time Factors | 12 | 2020 | 6240 | 0.360 |
Why?
| Hydrofluoric Acid | 2 | 2016 | 7 | 0.360 |
Why?
| Cross-Sectional Studies | 9 | 2020 | 4510 | 0.360 |
Why?
| Pharmaceutical Vehicles | 1 | 2010 | 11 | 0.360 |
Why?
| Propylene Glycol | 1 | 2010 | 9 | 0.360 |
Why?
| United States | 17 | 2023 | 12381 | 0.360 |
Why?
| Barium | 1 | 2009 | 25 | 0.360 |
Why?
| Surveys and Questionnaires | 4 | 2018 | 4661 | 0.360 |
Why?
| Acidosis, Lactic | 1 | 2010 | 29 | 0.350 |
Why?
| Explosive Agents | 1 | 2009 | 9 | 0.350 |
Why?
| Warfarin | 1 | 2010 | 136 | 0.350 |
Why?
| Liver Diseases, Alcoholic | 2 | 2007 | 86 | 0.350 |
Why?
| Imines | 2 | 2022 | 7 | 0.350 |
Why?
| Hypokalemia | 1 | 2009 | 30 | 0.350 |
Why?
| Risk Factors | 9 | 2017 | 8873 | 0.350 |
Why?
| Iatrogenic Disease | 1 | 2010 | 49 | 0.350 |
Why?
| Length of Stay | 3 | 2020 | 989 | 0.350 |
Why?
| Emetics | 2 | 2006 | 7 | 0.340 |
Why?
| Deception | 1 | 2009 | 15 | 0.340 |
Why?
| Random Allocation | 3 | 2007 | 339 | 0.340 |
Why?
| Benzoquinones | 2 | 2022 | 43 | 0.340 |
Why?
| Risk Assessment | 8 | 2017 | 3021 | 0.330 |
Why?
| Oximetry | 1 | 2009 | 80 | 0.330 |
Why?
| Odds Ratio | 7 | 2017 | 981 | 0.330 |
Why?
| Hypothermia, Induced | 1 | 2009 | 69 | 0.320 |
Why?
| Point-of-Care Systems | 1 | 2010 | 146 | 0.320 |
Why?
| Intellectual Disability | 1 | 2009 | 132 | 0.320 |
Why?
| Eyelashes | 1 | 2008 | 3 | 0.310 |
Why?
| Cyanoacrylates | 1 | 2008 | 4 | 0.310 |
Why?
| Hypoglycemia | 2 | 2010 | 402 | 0.310 |
Why?
| Adhesives | 1 | 2008 | 11 | 0.310 |
Why?
| Reference Values | 4 | 2017 | 751 | 0.310 |
Why?
| Detergents | 1 | 2008 | 43 | 0.310 |
Why?
| Animals | 20 | 2019 | 32737 | 0.300 |
Why?
| Cardiovascular System | 1 | 2009 | 125 | 0.300 |
Why?
| Publishing | 1 | 2009 | 129 | 0.300 |
Why?
| Polyethylene Glycols | 1 | 2012 | 574 | 0.300 |
Why?
| Brugada Syndrome | 1 | 2007 | 10 | 0.300 |
Why?
| Diazepam | 1 | 2007 | 27 | 0.300 |
Why?
| Clinical Laboratory Techniques | 1 | 2008 | 88 | 0.300 |
Why?
| Niacin | 1 | 2007 | 20 | 0.290 |
Why?
| Pediatrics | 1 | 2015 | 979 | 0.290 |
Why?
| Vitamin B Complex | 1 | 2007 | 37 | 0.290 |
Why?
| Mice, Inbred Strains | 4 | 2009 | 404 | 0.290 |
Why?
| Specimen Handling | 1 | 2008 | 157 | 0.290 |
Why?
| Thromboembolism | 1 | 2007 | 95 | 0.280 |
Why?
| Analgesics | 4 | 2017 | 157 | 0.280 |
Why?
| Brain Infarction | 1 | 2006 | 22 | 0.280 |
Why?
| Anticoagulants | 1 | 2010 | 542 | 0.280 |
Why?
| Self Report | 4 | 2021 | 696 | 0.280 |
Why?
| Hypoxia-Ischemia, Brain | 1 | 2006 | 26 | 0.270 |
Why?
| Randomized Controlled Trials as Topic | 5 | 2012 | 1233 | 0.270 |
Why?
| Nausea | 4 | 2014 | 106 | 0.270 |
Why?
| Intention | 1 | 2007 | 140 | 0.270 |
Why?
| Decontamination | 1 | 2006 | 23 | 0.270 |
Why?
| Age Factors | 7 | 2017 | 2951 | 0.270 |
Why?
| Amiodarone | 1 | 2005 | 23 | 0.270 |
Why?
| Venous Thrombosis | 1 | 2007 | 145 | 0.270 |
Why?
| Databases, Factual | 1 | 2010 | 1167 | 0.260 |
Why?
| Epilepsy | 2 | 2020 | 291 | 0.260 |
Why?
| Acute Kidney Injury | 1 | 2012 | 690 | 0.260 |
Why?
| Eating | 4 | 2017 | 363 | 0.260 |
Why?
| Vasospasm, Intracranial | 1 | 2005 | 17 | 0.260 |
Why?
| Biomarkers | 7 | 2021 | 3549 | 0.260 |
Why?
| Sodium Nitrite | 1 | 2005 | 36 | 0.250 |
Why?
| Education, Medical | 2 | 2021 | 226 | 0.250 |
Why?
| Hypoglycemic Agents | 2 | 2010 | 1035 | 0.250 |
Why?
| Drug Utilization | 5 | 2014 | 168 | 0.250 |
Why?
| Subarachnoid Hemorrhage | 1 | 2005 | 61 | 0.250 |
Why?
| Diagnostic Imaging | 1 | 2007 | 294 | 0.250 |
Why?
| Coma | 2 | 2006 | 30 | 0.250 |
Why?
| Reproducibility of Results | 5 | 2011 | 2819 | 0.250 |
Why?
| Insulin | 3 | 2019 | 2135 | 0.240 |
Why?
| Case-Control Studies | 4 | 2022 | 3099 | 0.230 |
Why?
| Hospitals, Urban | 5 | 2021 | 129 | 0.230 |
Why?
| Injections, Intraperitoneal | 4 | 2009 | 104 | 0.230 |
Why?
| Glasgow Coma Scale | 1 | 2004 | 147 | 0.230 |
Why?
| Anti-Anxiety Agents | 2 | 2020 | 44 | 0.230 |
Why?
| Animal Experimentation | 1 | 2003 | 6 | 0.230 |
Why?
| Fibrinolytic Agents | 2 | 2021 | 225 | 0.230 |
Why?
| Calcium Chloride | 1 | 2003 | 15 | 0.220 |
Why?
| Hospitals, Teaching | 3 | 2014 | 102 | 0.220 |
Why?
| Magnesium Sulfate | 1 | 2003 | 17 | 0.220 |
Why?
| Sensitivity and Specificity | 4 | 2010 | 1740 | 0.220 |
Why?
| Longevity | 3 | 2009 | 151 | 0.210 |
Why?
| Cardiopulmonary Resuscitation | 3 | 2018 | 223 | 0.210 |
Why?
| Placebos | 2 | 2014 | 198 | 0.210 |
Why?
| Umbilical Cord | 2 | 2021 | 84 | 0.210 |
Why?
| Opiate Substitution Treatment | 2 | 2020 | 102 | 0.210 |
Why?
| Desipramine | 1 | 2001 | 9 | 0.210 |
Why?
| Logistic Models | 3 | 2017 | 1877 | 0.200 |
Why?
| Phenylurea Compounds | 1 | 2022 | 84 | 0.200 |
Why?
| Hyperthermia, Induced | 1 | 2022 | 67 | 0.200 |
Why?
| Narcotic Antagonists | 2 | 2020 | 135 | 0.200 |
Why?
| Severity of Illness Index | 1 | 2009 | 2633 | 0.200 |
Why?
| Research Design | 3 | 2006 | 962 | 0.200 |
Why?
| Confidence Intervals | 4 | 2010 | 314 | 0.200 |
Why?
| Sinus Thrombosis, Intracranial | 1 | 2021 | 22 | 0.190 |
Why?
| Heart Atria | 1 | 2001 | 110 | 0.190 |
Why?
| Fractures, Bone | 2 | 2017 | 377 | 0.190 |
Why?
| Acute Disease | 2 | 2019 | 916 | 0.190 |
Why?
| Myocardial Contraction | 1 | 2001 | 328 | 0.180 |
Why?
| Mass Screening | 1 | 2007 | 1034 | 0.180 |
Why?
| Immunoglobulin Fragments | 1 | 1999 | 15 | 0.180 |
Why?
| Lysergic Acid Diethylamide | 1 | 1999 | 2 | 0.180 |
Why?
| Droperidol | 1 | 1999 | 4 | 0.180 |
Why?
| Wisconsin | 1 | 2020 | 91 | 0.180 |
Why?
| Lithium Carbonate | 1 | 1999 | 6 | 0.180 |
Why?
| Serotonin Syndrome | 1 | 1999 | 5 | 0.180 |
Why?
| Scorpion Stings | 1 | 1999 | 1 | 0.170 |
Why?
| Serotonin Receptor Agonists | 1 | 1999 | 27 | 0.170 |
Why?
| Nutritive Value | 1 | 2019 | 30 | 0.170 |
Why?
| Geriatric Assessment | 2 | 2011 | 177 | 0.170 |
Why?
| Starch | 1 | 2019 | 24 | 0.170 |
Why?
| Community Health Workers | 1 | 2020 | 46 | 0.170 |
Why?
| Ventricular Premature Complexes | 1 | 1999 | 22 | 0.170 |
Why?
| Administration, Oral | 4 | 2019 | 744 | 0.170 |
Why?
| Healthy Volunteers | 2 | 2019 | 187 | 0.170 |
Why?
| Thrombocytopenia | 1 | 2021 | 179 | 0.170 |
Why?
| Cannabidiol | 1 | 2020 | 59 | 0.170 |
Why?
| Metabolome | 1 | 2022 | 287 | 0.170 |
Why?
| Immune System | 1 | 2020 | 178 | 0.170 |
Why?
| Fallopian Tube Diseases | 1 | 1998 | 5 | 0.170 |
Why?
| Pregnancy, Tubal | 1 | 1998 | 4 | 0.170 |
Why?
| Alcoholism | 3 | 2011 | 716 | 0.160 |
Why?
| Cohort Studies | 7 | 2023 | 5051 | 0.160 |
Why?
| Abortifacient Agents, Nonsteroidal | 1 | 1998 | 19 | 0.160 |
Why?
| Munchausen Syndrome by Proxy | 1 | 1998 | 2 | 0.160 |
Why?
| Sex Factors | 5 | 2022 | 1758 | 0.160 |
Why?
| Dietary Carbohydrates | 1 | 2019 | 153 | 0.160 |
Why?
| Plant Extracts | 1 | 2020 | 159 | 0.160 |
Why?
| Snake Bites | 1 | 1999 | 54 | 0.160 |
Why?
| Anticonvulsants | 1 | 2020 | 182 | 0.160 |
Why?
| Faculty, Medical | 1 | 2021 | 236 | 0.160 |
Why?
| Chi-Square Distribution | 2 | 2017 | 513 | 0.160 |
Why?
| Sulfasalazine | 1 | 1998 | 21 | 0.160 |
Why?
| Dyspnea | 1 | 1999 | 202 | 0.160 |
Why?
| Drug Antagonism | 2 | 2009 | 8 | 0.150 |
Why?
| Fellowships and Scholarships | 1 | 2021 | 244 | 0.150 |
Why?
| Drug Therapy, Combination | 3 | 2011 | 965 | 0.150 |
Why?
| Drug Interactions | 4 | 2014 | 346 | 0.150 |
Why?
| Out-of-Hospital Cardiac Arrest | 1 | 2018 | 81 | 0.150 |
Why?
| Genome-Wide Association Study | 2 | 2023 | 1314 | 0.150 |
Why?
| Survival Rate | 3 | 2013 | 1679 | 0.150 |
Why?
| Incidence | 4 | 2013 | 2377 | 0.150 |
Why?
| Simulation Training | 1 | 2018 | 64 | 0.150 |
Why?
| Dietary Fats | 1 | 2019 | 305 | 0.150 |
Why?
| Methotrexate | 1 | 1998 | 229 | 0.150 |
Why?
| Continuity of Patient Care | 1 | 2020 | 254 | 0.150 |
Why?
| Gastrointestinal Agents | 1 | 1998 | 60 | 0.150 |
Why?
| Hypnotics and Sedatives | 1 | 1998 | 132 | 0.150 |
Why?
| Peptide Fragments | 1 | 2021 | 683 | 0.150 |
Why?
| Energy Intake | 1 | 2019 | 427 | 0.140 |
Why?
| Pain Management | 2 | 2017 | 289 | 0.140 |
Why?
| Ammonium Compounds | 1 | 2016 | 3 | 0.140 |
Why?
| Clinical Trials as Topic | 2 | 2012 | 957 | 0.140 |
Why?
| Fluorides | 1 | 2016 | 47 | 0.140 |
Why?
| Mice | 7 | 2009 | 15309 | 0.140 |
Why?
| Predictive Value of Tests | 3 | 2015 | 1825 | 0.140 |
Why?
| Cytochrome P-450 CYP2E1 Inhibitors | 1 | 2016 | 5 | 0.140 |
Why?
| Metabolic Clearance Rate | 2 | 2019 | 110 | 0.140 |
Why?
| Prenatal Care | 1 | 2019 | 262 | 0.140 |
Why?
| Ventricular Fibrillation | 1 | 2016 | 51 | 0.140 |
Why?
| Half-Life | 2 | 2019 | 146 | 0.140 |
Why?
| Survival Analysis | 3 | 2010 | 1240 | 0.140 |
Why?
| Pharmacovigilance | 1 | 2015 | 13 | 0.130 |
Why?
| Pilot Projects | 1 | 2020 | 1395 | 0.130 |
Why?
| Herniorrhaphy | 1 | 2016 | 51 | 0.130 |
Why?
| Milk | 1 | 2016 | 127 | 0.130 |
Why?
| Calcium | 2 | 2016 | 1125 | 0.130 |
Why?
| Genetic Variation | 1 | 2020 | 900 | 0.130 |
Why?
| Adverse Drug Reaction Reporting Systems | 1 | 2015 | 69 | 0.130 |
Why?
| Fatal Outcome | 2 | 2013 | 281 | 0.130 |
Why?
| Child Behavior | 1 | 2017 | 215 | 0.130 |
Why?
| Hemodialysis Units, Hospital | 1 | 1994 | 5 | 0.130 |
Why?
| Models, Biological | 2 | 2015 | 1689 | 0.120 |
Why?
| Ondansetron | 1 | 2014 | 8 | 0.120 |
Why?
| Liver Failure, Acute | 1 | 2015 | 60 | 0.120 |
Why?
| Patient Simulation | 1 | 2014 | 30 | 0.120 |
Why?
| Internship and Residency | 2 | 2014 | 964 | 0.120 |
Why?
| Hydrocodone | 1 | 2014 | 15 | 0.120 |
Why?
| Cytochrome P-450 CYP2D6 | 1 | 2014 | 25 | 0.120 |
Why?
| Curriculum | 1 | 2021 | 868 | 0.120 |
Why?
| Total Quality Management | 1 | 1994 | 60 | 0.120 |
Why?
| Personnel Staffing and Scheduling | 1 | 2015 | 80 | 0.120 |
Why?
| Prognosis | 3 | 2011 | 3390 | 0.120 |
Why?
| Physicians | 2 | 2020 | 781 | 0.120 |
Why?
| Transaminases | 1 | 2014 | 25 | 0.120 |
Why?
| Oxycodone | 1 | 2014 | 43 | 0.120 |
Why?
| Pregnancy Complications | 1 | 2019 | 446 | 0.120 |
Why?
| Acute Pain | 1 | 2014 | 33 | 0.120 |
Why?
| Guanfacine | 1 | 2013 | 2 | 0.120 |
Why?
| Remote Consultation | 1 | 2014 | 41 | 0.120 |
Why?
| Walking | 1 | 2017 | 420 | 0.120 |
Why?
| Clonidine | 1 | 2013 | 23 | 0.120 |
Why?
| Vitamins | 1 | 2015 | 156 | 0.120 |
Why?
| International Normalized Ratio | 2 | 2011 | 42 | 0.120 |
Why?
| Indazoles | 1 | 2014 | 59 | 0.110 |
Why?
| Cesium | 1 | 2013 | 17 | 0.110 |
Why?
| Food | 1 | 2015 | 160 | 0.110 |
Why?
| Attitude of Health Personnel | 1 | 2020 | 987 | 0.110 |
Why?
| Deoxycholic Acid | 1 | 2013 | 15 | 0.110 |
Why?
| Pain Measurement | 4 | 2019 | 460 | 0.110 |
Why?
| Lethargy | 1 | 2012 | 4 | 0.110 |
Why?
| Duloxetine Hydrochloride | 1 | 2012 | 8 | 0.110 |
Why?
| Dabigatran | 1 | 2012 | 24 | 0.110 |
Why?
| Pyrazoles | 1 | 2016 | 364 | 0.110 |
Why?
| Athletic Performance | 1 | 2013 | 42 | 0.110 |
Why?
| Chlorides | 1 | 2013 | 136 | 0.110 |
Why?
| Tachycardia | 1 | 2012 | 47 | 0.110 |
Why?
| Marijuana Abuse | 1 | 2015 | 207 | 0.110 |
Why?
| Sleep Stages | 1 | 2012 | 60 | 0.110 |
Why?
| Mycoses | 1 | 2013 | 67 | 0.110 |
Why?
| Sulfhydryl Reagents | 1 | 2012 | 11 | 0.100 |
Why?
| Dizziness | 1 | 2012 | 70 | 0.100 |
Why?
| Patient Discharge | 2 | 2016 | 784 | 0.100 |
Why?
| Data Collection | 2 | 2013 | 641 | 0.100 |
Why?
| Accidental Falls | 2 | 2011 | 150 | 0.100 |
Why?
| Arsenicals | 1 | 2012 | 24 | 0.100 |
Why?
| Sampling Studies | 1 | 2012 | 91 | 0.100 |
Why?
| Drug Combinations | 1 | 2013 | 291 | 0.100 |
Why?
| Follow-Up Studies | 3 | 2010 | 4507 | 0.100 |
Why?
| Information Systems | 1 | 2011 | 62 | 0.100 |
Why?
| Laparoscopy | 1 | 2016 | 401 | 0.100 |
Why?
| Sulfides | 1 | 2012 | 96 | 0.100 |
Why?
| Marijuana Smoking | 1 | 2015 | 219 | 0.100 |
Why?
| Arabia | 1 | 2011 | 2 | 0.100 |
Why?
| Hepatic Encephalopathy | 1 | 2011 | 21 | 0.100 |
Why?
| Levamisole | 1 | 2011 | 20 | 0.100 |
Why?
| Structure-Activity Relationship | 1 | 2012 | 516 | 0.100 |
Why?
| Dietary Supplements | 1 | 2015 | 466 | 0.100 |
Why?
| Immunocompromised Host | 1 | 2013 | 196 | 0.100 |
Why?
| Molecular Structure | 1 | 2012 | 434 | 0.100 |
Why?
| Drug Contamination | 1 | 2011 | 53 | 0.100 |
Why?
| Sports | 1 | 2013 | 177 | 0.090 |
Why?
| Universities | 1 | 2013 | 341 | 0.090 |
Why?
| Pharmacogenetics | 1 | 2012 | 155 | 0.090 |
Why?
| Glipizide | 1 | 2010 | 6 | 0.090 |
Why?
| Laboratories, Hospital | 1 | 2010 | 13 | 0.090 |
Why?
| Hepatitis, Alcoholic | 1 | 2010 | 13 | 0.090 |
Why?
| Troponin | 1 | 2010 | 45 | 0.090 |
Why?
| Glyburide | 1 | 2010 | 35 | 0.090 |
Why?
| Drug Prescriptions | 2 | 2016 | 241 | 0.090 |
Why?
| Crowding | 1 | 2010 | 38 | 0.090 |
Why?
| Watchful Waiting | 1 | 2010 | 55 | 0.090 |
Why?
| Adjuvants, Immunologic | 1 | 2011 | 205 | 0.090 |
Why?
| Body Weight | 1 | 2014 | 901 | 0.090 |
Why?
| Intensive Care Units, Pediatric | 1 | 2011 | 155 | 0.090 |
Why?
| Quetiapine Fumarate | 1 | 2009 | 23 | 0.090 |
Why?
| Aripiprazole | 1 | 2009 | 16 | 0.090 |
Why?
| Dibenzothiazepines | 1 | 2009 | 18 | 0.090 |
Why?
| Health Services Accessibility | 1 | 2015 | 773 | 0.090 |
Why?
| Risperidone | 1 | 2009 | 25 | 0.090 |
Why?
| Potassium | 1 | 2009 | 135 | 0.080 |
Why?
| Dogs | 1 | 2010 | 356 | 0.080 |
Why?
| Renal Dialysis | 1 | 2013 | 376 | 0.080 |
Why?
| Efficiency, Organizational | 1 | 2010 | 126 | 0.080 |
Why?
| Role | 1 | 2009 | 32 | 0.080 |
Why?
| Head Protective Devices | 1 | 2009 | 16 | 0.080 |
Why?
| Glutathione | 3 | 2022 | 314 | 0.080 |
Why?
| Workload | 1 | 2010 | 129 | 0.080 |
Why?
| Quality Control | 1 | 2009 | 153 | 0.080 |
Why?
| Acidosis | 2 | 2006 | 83 | 0.080 |
Why?
| Body Temperature | 1 | 2009 | 211 | 0.080 |
Why?
| Bibliometrics | 1 | 2009 | 50 | 0.080 |
Why?
| Diarrhea | 1 | 2009 | 176 | 0.080 |
Why?
| Quality Indicators, Health Care | 1 | 2011 | 287 | 0.080 |
Why?
| Skiing | 1 | 2009 | 41 | 0.080 |
Why?
| Students | 1 | 2013 | 504 | 0.080 |
Why?
| Informed Consent | 2 | 2006 | 162 | 0.080 |
Why?
| Pharmacy Service, Hospital | 1 | 2009 | 85 | 0.080 |
Why?
| Acetone | 1 | 2008 | 10 | 0.080 |
Why?
| Hair Preparations | 1 | 2008 | 2 | 0.080 |
Why?
| Bacitracin | 1 | 2008 | 6 | 0.080 |
Why?
| Adhesiveness | 1 | 2008 | 19 | 0.080 |
Why?
| Cause of Death | 1 | 2010 | 369 | 0.080 |
Why?
| Nylons | 1 | 2008 | 18 | 0.080 |
Why?
| Propylene Glycols | 1 | 2008 | 26 | 0.080 |
Why?
| Withholding Treatment | 1 | 2008 | 67 | 0.080 |
Why?
| Quinolones | 1 | 2009 | 99 | 0.080 |
Why?
| Substance Abuse Detection | 2 | 2021 | 61 | 0.080 |
Why?
| Equipment Design | 1 | 2009 | 515 | 0.080 |
Why?
| Drug Synergism | 1 | 2008 | 326 | 0.070 |
Why?
| Glycerol | 1 | 2008 | 87 | 0.070 |
Why?
| Cellulose | 1 | 2008 | 61 | 0.070 |
Why?
| Nephelometry and Turbidimetry | 1 | 2007 | 15 | 0.070 |
Why?
| Polypharmacy | 1 | 2008 | 75 | 0.070 |
Why?
| Laboratories | 1 | 2008 | 96 | 0.070 |
Why?
| Hospitalization | 2 | 2011 | 1762 | 0.070 |
Why?
| Military Personnel | 1 | 2014 | 532 | 0.070 |
Why?
| Phosphates | 1 | 2008 | 163 | 0.070 |
Why?
| Tissue Distribution | 2 | 2019 | 326 | 0.070 |
Why?
| Formates | 1 | 2006 | 12 | 0.070 |
Why?
| Periodicals as Topic | 1 | 2009 | 184 | 0.070 |
Why?
| Research | 2 | 2011 | 402 | 0.070 |
Why?
| Methanol | 1 | 2006 | 30 | 0.070 |
Why?
| Defibrillators | 1 | 2006 | 16 | 0.070 |
Why?
| Kidney Transplantation | 1 | 2013 | 573 | 0.070 |
Why?
| Combined Modality Therapy | 1 | 2009 | 1144 | 0.070 |
Why?
| Blindness | 1 | 2006 | 37 | 0.070 |
Why?
| Statistics, Nonparametric | 1 | 2007 | 392 | 0.070 |
Why?
| Aging | 2 | 2014 | 1653 | 0.070 |
Why?
| Vasopressins | 1 | 2006 | 64 | 0.070 |
Why?
| Naproxen | 1 | 2006 | 11 | 0.070 |
Why?
| Probability | 2 | 2010 | 296 | 0.070 |
Why?
| Respiratory Insufficiency | 1 | 2009 | 286 | 0.070 |
Why?
| Telemedicine | 1 | 2014 | 669 | 0.070 |
Why?
| Health Services for the Aged | 1 | 2006 | 70 | 0.070 |
Why?
| Ipecac | 1 | 2005 | 8 | 0.070 |
Why?
| Spinal Diseases | 1 | 2006 | 46 | 0.070 |
Why?
| Population Dynamics | 1 | 2006 | 135 | 0.070 |
Why?
| Respiration, Artificial | 1 | 2009 | 540 | 0.070 |
Why?
| Geriatrics | 1 | 2006 | 68 | 0.070 |
Why?
| Epinephrine | 1 | 2006 | 165 | 0.060 |
Why?
| Ibuprofen | 1 | 2006 | 75 | 0.060 |
Why?
| Hospitals, University | 1 | 2006 | 168 | 0.060 |
Why?
| Haplorhini | 1 | 2005 | 60 | 0.060 |
Why?
| Premedication | 1 | 2005 | 37 | 0.060 |
Why?
| Practice Guidelines as Topic | 2 | 2014 | 1403 | 0.060 |
Why?
| Water | 1 | 2008 | 395 | 0.060 |
Why?
| Blood Glucose | 2 | 2019 | 1931 | 0.060 |
Why?
| Spine | 1 | 2006 | 141 | 0.060 |
Why?
| Motivation | 1 | 2009 | 498 | 0.060 |
Why?
| Risk | 1 | 2007 | 842 | 0.060 |
Why?
| Single-Blind Method | 1 | 2005 | 259 | 0.060 |
Why?
| Fluoride Poisoning | 1 | 2004 | 4 | 0.060 |
Why?
| Resuscitation | 1 | 2006 | 215 | 0.060 |
Why?
| Guidelines as Topic | 1 | 2005 | 250 | 0.060 |
Why?
| Maltose | 1 | 2023 | 5 | 0.060 |
Why?
| Hydroxyzine | 1 | 2023 | 6 | 0.060 |
Why?
| Pregnancy | 3 | 2021 | 5653 | 0.060 |
Why?
| Health Policy | 1 | 2006 | 333 | 0.060 |
Why?
| Mycophenolic Acid | 1 | 2004 | 79 | 0.060 |
Why?
| Magnesium | 1 | 2004 | 147 | 0.060 |
Why?
| Sheep | 1 | 2006 | 763 | 0.060 |
Why?
| Aspirin | 1 | 2006 | 331 | 0.060 |
Why?
| Urea | 1 | 2023 | 76 | 0.050 |
Why?
| Survival | 1 | 2003 | 39 | 0.050 |
Why?
| Patient Participation | 1 | 2006 | 367 | 0.050 |
Why?
| Internet | 1 | 2007 | 594 | 0.050 |
Why?
| Prevalence | 3 | 2015 | 2300 | 0.050 |
Why?
| Urban Population | 2 | 2019 | 404 | 0.050 |
Why?
| Lactates | 1 | 2022 | 83 | 0.050 |
Why?
| Canada | 1 | 2023 | 337 | 0.050 |
Why?
| Sex Distribution | 2 | 2015 | 331 | 0.050 |
Why?
| Culture Techniques | 1 | 2001 | 82 | 0.050 |
Why?
| Blood Physiological Phenomena | 1 | 2021 | 13 | 0.050 |
Why?
| Breast Neoplasms | 1 | 2013 | 1883 | 0.050 |
Why?
| Neural Conduction | 1 | 2001 | 80 | 0.050 |
Why?
| Academic Medical Centers | 2 | 2016 | 415 | 0.050 |
Why?
| Hirudins | 1 | 2021 | 46 | 0.050 |
Why?
| Controlled Clinical Trials as Topic | 1 | 2020 | 26 | 0.040 |
Why?
| Infusions, Parenteral | 1 | 2020 | 37 | 0.040 |
Why?
| Certification | 1 | 2020 | 89 | 0.040 |
Why?
| Pirenzepine | 1 | 1999 | 8 | 0.040 |
Why?
| Scorpions | 1 | 1999 | 2 | 0.040 |
Why?
| Ambulatory Care | 1 | 2023 | 478 | 0.040 |
Why?
| Immunosuppressive Agents | 1 | 2004 | 674 | 0.040 |
Why?
| Temperature | 1 | 2022 | 602 | 0.040 |
Why?
| South America | 1 | 1999 | 56 | 0.040 |
Why?
| Blood Cell Count | 2 | 2013 | 52 | 0.040 |
Why?
| Narcotics | 1 | 1999 | 44 | 0.040 |
Why?
| Biological Availability | 1 | 2019 | 125 | 0.040 |
Why?
| Postprandial Period | 1 | 2019 | 90 | 0.040 |
Why?
| Rupture, Spontaneous | 1 | 1998 | 17 | 0.040 |
Why?
| Manikins | 1 | 2018 | 25 | 0.040 |
Why?
| Videotape Recording | 1 | 2018 | 31 | 0.040 |
Why?
| Central Nervous System Depressants | 1 | 1999 | 88 | 0.040 |
Why?
| Sorption Detoxification | 1 | 1998 | 3 | 0.040 |
Why?
| Analysis of Variance | 1 | 2001 | 1239 | 0.040 |
Why?
| Lipids | 1 | 2022 | 584 | 0.040 |
Why?
| Cholinesterase Inhibitors | 1 | 1998 | 26 | 0.040 |
Why?
| North America | 1 | 1999 | 268 | 0.040 |
Why?
| Dietary Proteins | 1 | 2019 | 132 | 0.040 |
Why?
| Laparotomy | 1 | 1998 | 95 | 0.040 |
Why?
| Feedback | 1 | 2018 | 151 | 0.040 |
Why?
| Recombinant Proteins | 1 | 2021 | 1258 | 0.040 |
Why?
| Cross-Over Studies | 1 | 2019 | 446 | 0.040 |
Why?
| Maternal Health Services | 1 | 2019 | 82 | 0.040 |
Why?
| Central Nervous System | 1 | 1999 | 241 | 0.040 |
Why?
| Socioeconomic Factors | 2 | 2015 | 1106 | 0.040 |
Why?
| Triglycerides | 1 | 2019 | 500 | 0.040 |
Why?
| Bipolar Disorder | 1 | 1999 | 204 | 0.040 |
Why?
| Registries | 2 | 2010 | 1788 | 0.040 |
Why?
| Oxidation-Reduction | 1 | 2019 | 910 | 0.030 |
Why?
| Hallucinogens | 1 | 2017 | 73 | 0.030 |
Why?
| Dialysis | 1 | 2015 | 24 | 0.030 |
Why?
| Centrifugation | 1 | 2015 | 31 | 0.030 |
Why?
| Verapamil | 1 | 2014 | 32 | 0.030 |
Why?
| Tennessee | 1 | 1994 | 41 | 0.030 |
Why?
| Observation | 1 | 2014 | 48 | 0.030 |
Why?
| Hematocrit | 1 | 1994 | 85 | 0.030 |
Why?
| International Classification of Diseases | 1 | 2015 | 117 | 0.030 |
Why?
| Program Evaluation | 1 | 2018 | 827 | 0.030 |
Why?
| Syndrome | 1 | 2015 | 339 | 0.030 |
Why?
| Protein Binding | 1 | 2020 | 1949 | 0.030 |
Why?
| Anesthetics, Local | 1 | 2014 | 89 | 0.030 |
Why?
| Erythropoietin | 1 | 1994 | 75 | 0.030 |
Why?
| Warfare | 1 | 2014 | 75 | 0.030 |
Why?
| Injections, Intralesional | 1 | 2013 | 31 | 0.030 |
Why?
| Hospitals, Veterans | 1 | 1994 | 239 | 0.030 |
Why?
| Salicylates | 1 | 2013 | 31 | 0.030 |
Why?
| Urinalysis | 1 | 2013 | 65 | 0.030 |
Why?
| Iron | 1 | 1994 | 242 | 0.030 |
Why?
| Nursing Staff, Hospital | 1 | 1994 | 121 | 0.030 |
Why?
| Hemoglobins | 1 | 1994 | 315 | 0.030 |
Why?
| Long QT Syndrome | 1 | 2013 | 61 | 0.030 |
Why?
| Therapeutic Irrigation | 1 | 2012 | 66 | 0.030 |
Why?
| Receptors, Opioid, mu | 1 | 2012 | 52 | 0.030 |
Why?
| Cytochrome P-450 Enzyme System | 1 | 2012 | 110 | 0.020 |
Why?
| Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2011 | 7 | 0.020 |
Why?
| Agranulocytosis | 1 | 2011 | 31 | 0.020 |
Why?
| False Negative Reactions | 1 | 2011 | 53 | 0.020 |
Why?
| Computer Simulation | 1 | 2015 | 903 | 0.020 |
Why?
| Leukoencephalopathies | 1 | 2011 | 21 | 0.020 |
Why?
| Fluid Therapy | 1 | 2012 | 128 | 0.020 |
Why?
| Insulin Resistance | 1 | 2019 | 1162 | 0.020 |
Why?
| Disease Outbreaks | 1 | 2014 | 317 | 0.020 |
Why?
| Toothache | 1 | 2010 | 5 | 0.020 |
Why?
| Gas Chromatography-Mass Spectrometry | 1 | 2011 | 129 | 0.020 |
Why?
| Quality of Health Care | 1 | 2015 | 580 | 0.020 |
Why?
| Immunoassay | 1 | 2011 | 99 | 0.020 |
Why?
| Models, Theoretical | 1 | 1994 | 534 | 0.020 |
Why?
| Drug Administration Routes | 1 | 2010 | 39 | 0.020 |
Why?
| Insurance Coverage | 1 | 2012 | 207 | 0.020 |
Why?
| Injections, Intravenous | 1 | 2010 | 208 | 0.020 |
Why?
| Neurologic Examination | 1 | 2010 | 118 | 0.020 |
Why?
| Patient Education as Topic | 1 | 1994 | 687 | 0.020 |
Why?
| Age Distribution | 1 | 2010 | 340 | 0.020 |
Why?
| Kidney Failure, Chronic | 1 | 1994 | 507 | 0.020 |
Why?
| Intestines | 1 | 2012 | 326 | 0.020 |
Why?
| Polymorphism, Genetic | 1 | 2012 | 629 | 0.020 |
Why?
| Safety | 1 | 2010 | 298 | 0.020 |
Why?
| Precision Medicine | 1 | 2012 | 356 | 0.020 |
Why?
| Ethanol | 1 | 2012 | 566 | 0.020 |
Why?
| Triage | 1 | 2010 | 192 | 0.020 |
Why?
| Clinical Competence | 1 | 2014 | 920 | 0.020 |
Why?
| Seasons | 1 | 2010 | 463 | 0.020 |
Why?
| Regression Analysis | 1 | 2010 | 971 | 0.020 |
Why?
| Disease Management | 1 | 2011 | 560 | 0.020 |
Why?
| Metabolomics | 1 | 2012 | 541 | 0.020 |
Why?
| Bilirubin | 1 | 2007 | 93 | 0.020 |
Why?
| Pulse | 1 | 2006 | 27 | 0.020 |
Why?
| Genotype | 1 | 2012 | 1854 | 0.020 |
Why?
| Blastomycosis | 1 | 2006 | 8 | 0.020 |
Why?
| Coronary Circulation | 1 | 2006 | 118 | 0.020 |
Why?
| Contraindications | 1 | 2006 | 85 | 0.020 |
Why?
| Amyloidosis | 1 | 2006 | 38 | 0.020 |
Why?
| Biopsy, Fine-Needle | 1 | 2006 | 65 | 0.020 |
Why?
| Electric Countershock | 1 | 2006 | 101 | 0.020 |
Why?
| Infant, Newborn | 2 | 2007 | 5170 | 0.020 |
Why?
| European Union | 1 | 2005 | 8 | 0.020 |
Why?
| Fever | 1 | 2007 | 281 | 0.020 |
Why?
| Disaster Planning | 1 | 2006 | 77 | 0.020 |
Why?
| Emergencies | 1 | 2006 | 151 | 0.020 |
Why?
| United States Food and Drug Administration | 1 | 2005 | 173 | 0.020 |
Why?
| Administration, Inhalation | 1 | 2006 | 642 | 0.020 |
Why?
| Renal Insufficiency | 1 | 2006 | 147 | 0.010 |
Why?
| Up-Regulation | 1 | 2007 | 837 | 0.010 |
Why?
| Pharmaceutical Preparations | 1 | 2006 | 169 | 0.010 |
Why?
| Swine | 1 | 2006 | 714 | 0.010 |
Why?
| Brain Injuries | 1 | 2009 | 449 | 0.010 |
Why?
| Phenotype | 1 | 2012 | 2891 | 0.010 |
Why?
| Mice, Inbred ICR | 1 | 2004 | 111 | 0.010 |
Why?
| Lupus Nephritis | 1 | 2004 | 55 | 0.010 |
Why?
| In Vitro Techniques | 1 | 2004 | 1049 | 0.010 |
Why?
| Blood Pressure | 1 | 2006 | 1618 | 0.010 |
Why?
| Miosis | 1 | 1999 | 3 | 0.010 |
Why?
| Pupil | 1 | 1999 | 13 | 0.010 |
Why?
| Hemodynamics | 1 | 2004 | 982 | 0.010 |
Why?
| Chronic Disease | 1 | 2004 | 1619 | 0.010 |
Why?
| Algorithms | 1 | 2004 | 1505 | 0.010 |
Why?
| Neoplasms | 1 | 2006 | 2147 | 0.010 |
Why?
|
|
Heard's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|